English

BioStock: Alligator’s CEO on current development and the rights issue

Report this content

The recent phase II success with mitazalimab means that Alligator Bioscience can now start preparing for phase III. Besides mitazalimab, the Lund-based biotech also has other promising projects in its pipeline. Now, Alligator is carrying out a SEK 150.9 million rights issue to bring all of the projects even further. BioStock talked to CEO Søren Bregenholt to discuss the rights issue in more depth.

Read the article at biostock.se:

Alligator’s CEO on current development and the rights issue - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Alligator’s CEO on current development and the rights issue
Tweet this